Using engineered cell libraries to reveal the best drug targets

Gene editing
Kevin Holden
Kevin Holden

In this webinar, hosted by DDW and supported by Synthego, Kevin Holden, Ph.D, Head of Science, Synthego will explain how the company’s engineered cell libraries enable screening more widely and efficiently to increase the pace and impact of target discovery.

Join this free exclusive event on 9 November at 3pm GMT to hear speakers Kevin Holden and Teddy Lin, Associate Director, Commercial Strategy, Synthego.

Teddy Lin
Teddy Lin

CRISPR-based knockouts are the gold-standard genetic perturbation method in target identification and validation. However, efficient CRISPR knockout editing and transfection for arrayed screening require specialised skills and infrastructure that your organisation may not have.

What if you could receive ready-to-use CRISPR-edited cells without needing to handle, optimise, and transfect your CRISPR library?

 

Register for free here.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free